Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Sell
9
NONOF Quote, Financials, Valuation and Earnings
Last price:
$87.80
Seasonality move
:
9.09%
Day range:
$83.80 - $87.55
52-week range:
$79.15 - $149.55
Dividend yield:
1.7%
P/E ratio:
27.56x
P/S ratio:
9.65x
P/B ratio:
20.92x
Volume:
3.1K
Avg. volume:
69.4K
1-year change:
-19.54%
Market cap:
$377.7B
Revenue:
$33.7B
EPS (TTM):
$3.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$11.1B | -- | 19.31% | -- | -- |
|
ASND
Ascendis Pharma AS
|
$106.9M | -$1.31 | -31.79% | -15.93% | $191.30 |
|
GLTO
Galecto
|
-- | -$2.82 | -- | -51.46% | -- |
|
GMAB
Genmab AS
|
$877.6M | $0.39 | 29.03% | 152.19% | $36.56 |
|
LLY
Eli Lilly and
|
$14B | $5.43 | 49.68% | 124.93% | $984.05 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$85.04 | -- | $377.7B | 27.56x | $0.52 | 1.7% | 9.65x |
|
ASND
Ascendis Pharma AS
|
$134.43 | $191.30 | $8B | -- | $0.00 | 0% | 21.63x |
|
GLTO
Galecto
|
$5.28 | -- | $7M | -- | $0.00 | 0% | -- |
|
GMAB
Genmab AS
|
$22.19 | $36.56 | $14.1B | 21.09x | $0.00 | 0% | 5.01x |
|
LLY
Eli Lilly and
|
$787.22 | $984.05 | $747.3B | 85.10x | $1.30 | 0.66% | 17.42x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
32.1% | 1.212 | 1.64% | 0.74x |
|
ASND
Ascendis Pharma AS
|
114.08% | 1.789 | 9.87% | 0.81x |
|
GLTO
Galecto
|
-- | 1.479 | -- | -- |
|
GMAB
Genmab AS
|
-- | 0.544 | -- | 5.15x |
|
LLY
Eli Lilly and
|
68.61% | 1.159 | 3.9% | 0.63x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NONOF
Novo Nordisk AS
|
$8.8B | $5B | 65.63% | 88.95% | 49.37% | $4.7B |
|
ASND
Ascendis Pharma AS
|
$51.3M | -$106.4M | -89.94% | -880.05% | -125.93% | -$110.6M |
|
GLTO
Galecto
|
-- | -$3.8M | -- | -- | -- | -$3.7M |
|
GMAB
Genmab AS
|
$776.2M | $312.3M | 14.86% | 14.86% | 31.35% | $301.5M |
|
LLY
Eli Lilly and
|
$9.3B | $4.4B | 21.5% | 66.4% | 15.57% | -$458.9M |
Novo Nordisk AS vs. Competitors
-
Which has Higher Returns NONOF or ASND?
Ascendis Pharma AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of -171.53%. Novo Nordisk AS's return on equity of 88.95% beat Ascendis Pharma AS's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.14% $0.90 $26.6B ASNDAscendis Pharma AS80.63% -$1.89 $772.2M -
What do Analysts Say About NONOF or ASND?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 11.94%. On the other hand Ascendis Pharma AS has an analysts' consensus of $191.30 which suggests that it could grow by 42.3%. Given that Ascendis Pharma AS has higher upside potential than Novo Nordisk AS, analysts believe Ascendis Pharma AS is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 ASNDAscendis Pharma AS12 1 0 -
Is NONOF or ASND More Risky?
Novo Nordisk AS has a beta of 0.510, which suggesting that the stock is 48.959% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.145%.
-
Which is a Better Dividend Stock NONOF or ASND?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.7%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or ASND?
Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Ascendis Pharma AS quarterly revenues of $63.6M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.56x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.65x versus 21.63x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS9.65x 27.56x $10.5B $4B ASNDAscendis Pharma AS21.63x -- $63.6M -$109.1M
-
Which has Higher Returns NONOF or GLTO?
Galecto has a net margin of 38.28% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 88.95% beat Galecto's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.14% $0.90 $26.6B GLTOGalecto-- -$3.39 -- -
What do Analysts Say About NONOF or GLTO?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 11.94%. On the other hand Galecto has an analysts' consensus of -- which suggests that it could grow by 89.39%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 GLTOGalecto0 0 0 -
Is NONOF or GLTO More Risky?
Novo Nordisk AS has a beta of 0.510, which suggesting that the stock is 48.959% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NONOF or GLTO?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.7%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or GLTO?
Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Galecto quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Galecto's net income of -$3.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.56x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.65x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS9.65x 27.56x $10.5B $4B GLTOGalecto-- -- -- -$3.9M
-
Which has Higher Returns NONOF or GMAB?
Genmab AS has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 22.85%. Novo Nordisk AS's return on equity of 88.95% beat Genmab AS's return on equity of 14.86%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.14% $0.90 $26.6B GMABGenmab AS95.07% $0.29 $4.8B -
What do Analysts Say About NONOF or GMAB?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 11.94%. On the other hand Genmab AS has an analysts' consensus of $36.56 which suggests that it could grow by 64.74%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 GMABGenmab AS2 5 0 -
Is NONOF or GMAB More Risky?
Novo Nordisk AS has a beta of 0.510, which suggesting that the stock is 48.959% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.966, suggesting its less volatile than the S&P 500 by 3.369%.
-
Which is a Better Dividend Stock NONOF or GMAB?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.7%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or GMAB?
Novo Nordisk AS quarterly revenues are $10.5B, which are larger than Genmab AS quarterly revenues of $816.4M. Novo Nordisk AS's net income of $4B is higher than Genmab AS's net income of $186.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.56x while Genmab AS's PE ratio is 21.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.65x versus 5.01x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS9.65x 27.56x $10.5B $4B GMABGenmab AS5.01x 21.09x $816.4M $186.6M
-
Which has Higher Returns NONOF or LLY?
Eli Lilly and has a net margin of 38.28% compared to Novo Nordisk AS's net margin of 8.48%. Novo Nordisk AS's return on equity of 88.95% beat Eli Lilly and's return on equity of 66.4%.
Company Gross Margin Earnings Per Share Invested Capital NONOFNovo Nordisk AS84.14% $0.90 $26.6B LLYEli Lilly and81.02% $1.07 $45.4B -
What do Analysts Say About NONOF or LLY?
Novo Nordisk AS has a consensus price target of --, signalling upside risk potential of 11.94%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25%. Given that Eli Lilly and has higher upside potential than Novo Nordisk AS, analysts believe Eli Lilly and is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NONOFNovo Nordisk AS0 0 0 LLYEli Lilly and15 6 0 -
Is NONOF or LLY More Risky?
Novo Nordisk AS has a beta of 0.510, which suggesting that the stock is 48.959% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.
-
Which is a Better Dividend Stock NONOF or LLY?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.7%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Novo Nordisk AS pays 37.96% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NONOF or LLY?
Novo Nordisk AS quarterly revenues are $10.5B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Novo Nordisk AS's net income of $4B is higher than Eli Lilly and's net income of $970.3M. Notably, Novo Nordisk AS's price-to-earnings ratio is 27.56x while Eli Lilly and's PE ratio is 85.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 9.65x versus 17.42x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NONOFNovo Nordisk AS9.65x 27.56x $10.5B $4B LLYEli Lilly and17.42x 85.10x $11.4B $970.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 10
IonQ [IONQ] is up 11.01% over the past day.
Sell
45
COLL alert for Jan 10
Collegium Pharmaceutical [COLL] is down 1.05% over the past day.
Sell
30
EDN alert for Jan 10
Empresa Distribuidora y Comercializadora Norte SA [EDN] is down 0.77% over the past day.
